A new method for the serological diagnosis of hepatitis E virus (HEV) infection based on neutralization of the virus in cell culture was developed. The test involves a short incubation of the virus in the presence of the serum sample to be tested and permissive cells. With viral replication being limited and without a cytopathic effect, viral growth in cells is evaluated by reverse transcription and PCR. The specificity of the test was established by studying sera from healthy individuals and patients with hepatitis living in France, where autochthonous hepatitis E is unknown. The kinetics and sensitivity of antibody detection were evaluated during the experimental infection of monkeys. Neutralizing antibodies were found in 79% of patients during an outbreak of hepatitis E and in 43% of patients with sporadic, acute non-A, non-B (without anti-hepatitis C virus antibodies) hepatitis. This neutralization assay is proposed as a confirmatory test for the available enzymelinked immunosorbent assay (ELISA), which is now recognized as giving many false-positive reactions, and to improve identification of new hepatitis viruses since false-negative reactions with HEV ELISA are also encountered.
Hepatitis E is an important health problem in developing countries. It occurs in both epidemic and sporadic forms. A 20% mortality rate has been observed among women infected during the third trimester of pregnancy (2) . In developed countries, where the hepatitis E virus (HEV) has never been identified in patients with autochthonous cases, it remains unclear whether subclinical or unrecognized infections can account for the approximately 2% of blood donors with anti-HEV antibodies (Ab) (4) . HEV transmission has recently been suspected in hemodialysis patients (4) , drug addicts (5), and homosexual men (8) . All these situations were incriminated as possibly facilitating the spread of HEV infection, but only serological investigations (by enzyme-linked immunosorbent assay [ELISA] ) have been taken into account.
It now appears that the recently introduced HEV serology which solely involves ELISA technology is not satisfactory. Indeed, early or late anti-HEV human Ab collected from patients with a well-documented epidemic hepatitis E do not always compete with serum samples found to be ELISA positive (9) . Moreover, in a polycentric evaluation of ELISA for Ab to HEV with a serum panel, the results of 11 different assays were largely discordant (6) . However, it is not yet possible to compare this test with an internationally recognized reference test or with a confirmatory assay. Since the immunity in HEV infection has recently been shown to be of a humoral nature (11, 14) , a test providing evidence of Ab with virus neutralization capacity should theoretically offer a better specificity than ELISA, which involves the detection of the majority or all of the Ab produced against an infectious agent. Moreover, sequence comparisons have revealed at least two distinct HEV groups (3) , and the number of HEV serotypes is not yet known; seroneutralization tests could be more discriminating than ELISA for strain identification. Finally, even though false-positive reactions are now well-recognized (6, 9) , the sensitivity of ELISA remains undefined. Some cases of non-A, non-B, non-C (non-A-C) hepatitis could not be recognized as being due to HEV, and the reason why the ELISA positivity does not exceed 20% in areas where HEV infection is highly endemic remains unknown (1) . Whether these situations represent false-negative reactions and reflect limitations of current HEV serological tests is unknown. The absence of anti-HEV Ab in patients with non-A-C hepatitis is essential for supporting the existence of other hepatotropic viral agents (12, 16) .
In 1987 we showed with immunological tools that PLC/ PRF/5, a carcinomatous hepatocyte cell line, was able to replicate HEV (10) . Cloning of the virus and PCR development (13) confirmed our preliminary results and permitted us to improve the detection of HEV in cell culture (7) . In this report the specificity and the sensitivity of a rapid seroneutralization assay (rSNA) were evaluated, and the reactivities of the presumed heterologous HEV strains derived from different geographical regions were analyzed. Finally, the prevalence of anti-HEV neutralizing Ab was determined in patients with epidemic and sporadic cases of non-A-C hepatitis in different countries, and the results were compared with those obtained by ELISA.
MATERIALS AND METHODS
Cell culture. PLC/PRF/5, a human hepatocarcinoma cell line, was used for culture. Cells were grown in Eagle's minimal essential medium (Gibco BRL, Gaithersburg, Md.) supplemented with 10% heat-inactivated fetal calf serum, and the cells were incubated at 37°C with 5% CO 2 . For virus titration or neutralization assays, the trypsinized cells were seeded out in 24-well flat-bottom culture plates at a concentration of 10 5 cells per well. Virus stock. The reference Pakistani HEV strain SAR-55 (15) was from a fecal specimen obtained from an experimentally infected rhesus monkey at day 21 after intravenous inoculation. The Moroccan HEV strain F23 was from a fecal specimen collected from a 28-year-old male patient with epidemic hepatitis E.
Both stool samples were prepared in a 10% (wt/vol) phosphate-buffered saline suspension. After centrifugation, the supernatant was filtered through a 0.22-m-pore-size Millipore filter and was titrated on PLC/PRF/5 cell culture. These virus stocks were distributed and stored at Ϫ80°C until the neutralization assay was performed.
Monkey sera. Preinoculation and postinoculation sera (11) were obtained from four 3-to 4-year-old cynomolgus monkeys (monkeys G21A, 713A, 933A, and 967B) born in captivity, collected before and after infection with the SAR-55 strain, and from one cynomolgus monkey (monkey 479A) which had been inoculated 1 year before with an Algerian strain. The sera were collected at different times between days 11 and 104 after inoculation. The sera was kept frozen in aliquots at Ϫ90°C.
Human sera. Fifty-five serum samples from healthy individuals living in the suburbs of Paris, where the immigrant density is about 5%, were tested as negative controls. In order to evaluate the specificity of the neutralization test for patients with liver diseases, we used sera from 35 patients living in France, 9 with anti-hepatitis A virus (anti-HEV) immunoglobulin M (IgM) Ab, 11 with antihepatitis B virus core antigen (anti-HBc) IgM Ab, 5 with anti-hepatitis C virus (anti-HCV) Ab, 6 with anti-HBc plus anti-HCV Ab, and 4 with nonviral liver pathology. Twenty-nine serum samples were collected from patients with hepatitis during an HEV outbreak in Morocco (Casablanca area) during the summer of 1994, and 37 serum samples were collected from patients hospitalized in 1992 and 1993 in Abidjan (Ivory Coast) with non-A, non-B hepatitis without anti-HCV Ab (patients with a high risk of HEV infection). At last, to delineate the ability of the HEV rSNA to be used as a confirmatory test, 45 serum samples from French patients suffering from non-A-C hepatitis (some of them coming back from countries where HEV is endemic) were tested by ELISA and rSNA and the results were compared. Sera were aliquoted and frozen at Ϫ30°C.
Rapid assay for neutralizing anti-HEV antibodies. About 100 cell culture infectious doses of HEV were added to a decomplemented (30 min at 56°C) 1:10 dilution of the sera to be tested. After incubation at 37°C for 1 h, the mixtures were inoculated into a monolayer of the PLC/PRF/5 cell line in a 24-well plate. After adsorption for 2 h at 37°C, the cells were washed three times with the Hank's solution, and RNA was extracted with TRIzol reagent (Gibco BRL) according to the manufacturer's instructions. Briefly, 250 l of TRIzol reagent was added to each inoculated culture well. The mixture was transferred, homogenized, and incubated for 5 min at room temperature. Then, 50 l of chloroform was added. The mixture was vigorously shaken for 15 s and incubated at room temperature for 3 min. After centrifugation at 12,000 ϫ g for 15 min at 4°C, the aqueous phase was transferred. The RNA from the aqueous phase was precipitated with an equal volume of isopropyl alcohol at room temperature for 10 min and was centrifuged at 12,000 ϫ g for 10 min at 4°C. After removing the supernatant, the RNA pellet was washed once with 800 l of 75% ethanol and recentrifuged. At the end of the procedure, the RNA pellet was briefly dried and dissolved in 20 l of diethylpyrocarbonate-treated water. After denaturation for 10 min at 70°C, reverse transcription (RT) and PCR were performed. Two sets of sense and antisense synthetic oligonucleotide primers were used for the detection of the HEV genome. The sequences were of the ORF2 of the HEV genome. The outer primers were 5Ј-GAG GCA GGC ACA ACT AAA GC-3Ј (S1) and 5Ј-AAG AAG GGG GGC ACA AG-3Ј (A1), and the internal primers were 5Ј-GCA CCG GGT CGC TAT TTC-3Ј (S2) and 5Ј-TGA AGC TCA GCG ACA GTA GA-3Ј (A2).
For RT, 20 l of a mixture containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM (each) deoxynucleotide triphosphate (Pharmacia, Uppsala, Sweden), 10 pmol of antisense primer A1, 20 U of recombinant RNase inhibitor (Rnasin; Promega, Madison, Wis.), 200 U of Moloney murine leukemia virus reverse transcriptase (Gibco BRL), and 5 l of heat-denatured RNA was prepared. The mixture was incubated at 37°C for 1 h, heated for 5 to 10 min at 95°C, and immediately chilled in ice.
The first round of PCR was carried out with a total reaction volume of 50 l containing 5 l of cDNA in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin, 0.2 mM (each) deoxynucleoside triphosphates, 50 pmol of each outer primer (S1 and A1), and 2 U of Taq DNA polymerase (Eurobiotaq; Eurobio, Paris, France). The reaction mixture was overlaid with 30 l of mineral oil. Amplification was carried out according to the following cycling program: denaturation at 94°C for 1 min, annealing at 60°C for 2 min, and extension at 72°C for 2 min for 35 cycles, followed by a final extension at 72°C for 8 min, all of which were performed in a thermal cycler (LEMP, Andover, Hampshire, England). In the second round of PCR, 5 l of the first PCR product was amplified with internal primers (S2 and A2) by the amplification procedure described above. The PCR products (216 bp) were separated by electrophoresis in a 1.5% agarose gel containing ethidium bromide and were submitted to Southern blotting on a Hybond-N ϩ membrane (Amersham, Little Chalfont, England). The specificity of the observed band was eventually verified by hybridization with a complete ORF2 sequence of the HEV genome (dUTP fluorescein; Amersham) prepared from a recombinant plasmid (a gift from R. H. Purcell, Bethesda, Md.).
ELISA for anti-HEV IgG Ab. Anti-HEV serum IgG was detected by solidphase ELISA with a commercially available ELISA kit (Abbott Laboratories, North Chicago, Ill.) and, in some cases, with the Biotech kit (Diagnostic Biotechnology, Singapore). Both tests were carried out according to the manufacturer's instructions. Labelled anti-IgG reagents of both kits were verified to work with cynomolgus monkey IgG as well as with human IgG.
RESULTS
Evidence of HEV seroneutralization in cell culture. When the cell inoculation was carried out in the presence of preimmune monkey sera, the HEV genome was always detected by RT-PCR at all steps of the cell culture. When the sera collected from the same animals after HEV infection and the appearance of an elevation in transaminase levels were introduced, the viral genome was undetectable immediately after washing at the end of the inoculation step; the HEV genome remained undetectable while the cell culture was maintained for at least 10 days. Such a nested PCR always gave clear and reproducible results with uninfected as well as infected cells. An example of an RT-PCR used to identify HEV cell infection in an rSNA is shown in Fig. 1 .
Specificity and sensitivity of the rSNA. The specificity of the rSNA was examined with samples collected from preinoculated monkeys and from healthy individuals in a low-risk population. None of the five preinoculated monkey serum samples neutralized HEV in cell culture. Among 55 serum samples from a healthy French population, only 1 serum sample (1.8%) remained repeatedly neutralizing. However, this population included some Africans living in France, and the subject with neutralizing Ab can be considered as having been contaminated overseas.
Patients with liver diseases usually display increased IgG levels in their serum and are known to more frequently have false-positive reactions than patients with other diseases. Therefore, sera from 35 French patients with liver diseases were investigated by the anti-HEV rSNA. Only one presented a neutralizing activity; since this serum sample also had antiHBc and anti-HCV Ab, it could have been collected from a patient with a high risk of virus transmission ( Table 1) . The sensitivity of the rSNA was tested with sera collected from monkeys at different times during the experimental HEV infection, and the results were compared with those obtained by ELISA (Table 2 ). Among four of the five recently inoculated monkeys, the neutralizing antibody appeared 7 to 33 days (mean, 15.5 days) earlier than the antibody detected by ELISA. For only one monkey, ELISA was found to be positive 7 days earlier than rSNA.
Cross-reactivity of the rSNA. Convalescent-phase sera derived from four monkeys experimentally infected with the Pakistani strain (SAR-55) neutralized the infectivity of the homologous strain, but also the infectivity of the Moroccan strain (F23). Eight serum samples derived from Moroccan patients with hepatitis E neutralized the infectivity of the F23 strain, as well as that of the SAR-55 strain (data not shown). However, the sera from a monkey previously infected with an Algerian strain neutralized the SAR-55 strain, but only an elusive positive reaction was noted with the F23 strain, whereas an ELISA kit failed to detect anti-HEV Ab (Table 3) .
rSNA as a confirmatory test for HEV ELISA and a discriminatory test for non-A, non-B, non-C, non-E hepatitis. Sera from 29 patients with a liver pathology during an outbreak of waterborne hepatitis in Morocco and 37 patients hospitalized with non-A, non-B hepatitis (without anti-HCV Ab) in Ivory Coast, where HEV infection is endemic, were studied by rSNA and ELISA and the results were compared (Table 4) . Among the patients with epidemic cases of infection, 23 of 29 (79%) were found to produce neutralizing Ab (P Ͻ 0.0001), and all the ELISA-positive sera except one were confirmed to be positive by rSNA. In patients with sporadic cases of non-A, non-B hepatitis without anti-HCV Ab, 16 of 37 (43%) had neutralizing Ab (P Ͻ 0.0001), but 4 of these found to be negative by ELISA produced Ab neutralizing HEV.
Since HEV serology is an essential step for the identification of new hepatitis viruses and since the presence of anti-HEV can be due to a past infection, the same investigations were performed with sera from patients with acute or chronic hepatitis, but living in France, where autochthonous hepatitis E is unknown (Table 4 ). Of the 45 French patients with non-A-C hepatitis whose sera were analyzed, 5 were found to be ELISA positive, and 4 of these were confirmed to be positive by rSNA. However, 7 of 45 patients who appeared negative by ELISA had Ab neutralizing HEV. For the four patients positive by both tests, hepatitis E had been contracted in countries where hepatitis E is endemic (Tunisia and Morocco); one of them, an adult male, died after liver transplantation. Among the seven patients with neutralizing Ab undetectable by ELISA, the HEV infection was epidemiologically documented as an imported disease for six of them, including a pregnant woman who went through a therapeutic abortion for fetal malformations at her 23rd week of pregnancy; the malformations were possibly coincident with her HEV infection. 
a Day postinoculation that serum was obtained from a monkey infected with an Algerian strain. 
DISCUSSION
In most viral diseases, the appearance of neutralizing Ab coincides with the onset of recovery. The neutralization assay is, as a rule, the reference test for viral serology. Neutralization involves only one or a limited number of epitopes on the viral surface and, frequently, Ab of defined classes or subclasses. In the case of HEV infection, convalescent-phase sera have been able to neutralize experimental infection (11, 14) . Therefore, the neutralization assay appears to be a possible "gold standard" for HEV serology and to be especially helpful, since ELISA displays a poor specificity (6, 9) . The replication of an enterically transmitted non-A, non-B hepatitis virus (known today as HEV) in PLC/PRF/5 hepatocyte cells has been established by immunological means (10); this first approach has now been confirmed by PCR, as shown here. The persistence of adsorbed virus at the surface of the cell is excluded, since infected PLC/PRF/5 cells inoculated into SCID mice gave in 2 months a voluminous cutaneous tumor in which the virus was always detectable (unpublished data).
This cell culture gave us the opportunity to develop a neutralization assay. However, the lack of a cytopathic effect and the low level of viral replication (the number of virions inoculated was only multiplied by 10 2 to 10 3 ) (7) oblige us to use the sensitive RT-PCR to detect the presence of virus and to determine the neutralization effect in cell culture. All neutralization tests are based on the assumption that the detected Ab block the replication of viruses, regardless of the stage of cell infection at which the effect occurs. When the neutralization of HEV was compared after a period of cell culture of 3 to 7 days following the in vitro infection or immediately at the end of the inoculation period, an identical result was always obtained. Therefore, this rapid modality was retained. Under these conditions, blocking of the fixation of HEV on the hepatocyte viral receptor must be considered. Stool extracts were used as the source of virus for rSNA. Reproducible results with the cell culture-derived virus have not yet been obtained, for unexplained reasons. As a matter of fact, the rSNA appears to afford a means for the identification of a new HEV marker, the neutralizing Ab.
The sensitivity of the rSNA was documented in experimentally infected cynomolgus monkeys. In four of five animals, neutralizing Ab appeared before the Ab revealed by ELISA, and their detection was correlated with the disappearance of HEV from serum in RT-PCR (data not shown). The specificity of rSNA was established with sera from healthy individuals living in France, where the disease is not endemic, and also with sera from patients suffering from liver diseases, infectious or not. The ability to use rSNA for the diagnosis of HEV infection was tested during an HEV outbreak occurring in Morocco: anti-HEV neutralizing Ab were detected during the disease in 79% of patients, with a good correlation of the results of rSNA with those of ELISA. When the test was applied to sera from patients hospitalized with a non-A, non-B, presumed non-C hepatitis in a country (Ivory Coast) where HEV infection is endemic, the percentage of patients with neutralizing Ab fell to 43%, whereas ELISA incriminated an HEV infection in 70% of the patients. In these cases of disease in an area where the disease in endemic, a high level of unspecific reactions is strongly suspected.
Finally, the rSNA was tested as a confirmatory test for ELISA with 45 serum samples collected from different French patients suffering from acute or chronic non-A-C hepatitis, with hepatitis C being excluded by PCR. Five patients (11%) had anti-HEV antibodies by ELISA, and these results were confirmed by rSNA for four patients. The four patients with Ab detectable by both methods were returning from countries where HEV infection is endemic. A false-positive reaction by the ELISA is incriminated for the fifth patient. Independently of the confirmatory capacities of our rSNA, this test displayed anti-HEV Ab in 16% of patients believed to be suffering from non-A-C and non-E hepatitis when the negativity of the HEV ELISA was considered.
Therefore, the rSNA should be useful for the discrimination of non-A-C and non-E hepatitis in which determination of the infecting virus by a subtraction is compulsory. To this aim, rSNA permits us to confirm a positive HEV ELISA result as well as to reveal anti-HEV Ab undetectable by this test. Concerning the cross-reactivity of rSNA, no differences were noted between a Moroccan strain and a Pakistani strain. However, a monkey serum sample collected after a past occult infection with an Algerian strain did not clearly neutralize the Moroccan strain. In contrast, the Pakistani strain (SAR-55) was always neutralized. Consequently, the SAR-55 strain, which seems to possess a well-conserved and/or accessible epitope, should be used for the rSNA. A panel of HEV strains is under investigation in order to evaluate the range of rSNA. With paired monkey sera, neutralizing Ab appeared earlier than Ab detected by ELISA for four of five inoculated animals. The respective roles played by human IgM and IgG in rSNA remain to be investigated. However, rSNA remains a complex technique, which complicates its implementation as a routine procedure. Nevertheless, it should be a useful reference for vaccine development and should help to improve the specificity of ELISA, which remains unsufficient.
In conclusion, rSNA appears to be a more specific and more sensitive test than ELISA. It should permit confirmation of ELISA, whose results are too frequently incorrect to establish the seroepidemiology of HEV, and permit a better discrimination of non-A, non-B, non-C, and non-E hepatitis, particularly in developing countries where HEV is endemic and for imported cases in developed countries.
